SPRINGFIELD, Mo. – February 17, 2026 – Sharlin Health and Neurology released updated educational guidance regarding hormone replacement therapy (HRT) for men and women, addressing common misconceptions and outlining current clinical standards for evaluation and treatment.

According to the practice, confusion surrounding hormone therapy has persisted for more than two decades, largely influenced by early interpretations of findings from the Women’s Health Initiative (WHI). The WHI study, published in the early 2000s, evaluated hormone therapy in a population of women whose average age was 63 and who were often more than a decade beyond menopause. Many participants had preexisting cardiovascular disease, and the formulations used included synthetic hormones administered orally.

Sharlin Health and Neurology noted that modern hormone therapy protocols differ substantially from those used in the WHI. Contemporary approaches may include bioidentical hormone formulations, individualized dosing strategies, and delivery methods selected based on patient-specific risk factors and clinical goals. Current evidence supports a more nuanced understanding of timing, formulation, and route of administration in evaluating potential risks and benefits.

The practice emphasized that hormone health affects both women and men. In women, therapy considerations may extend beyond estradiol to include progesterone and, in some cases, testosterone, depending on clinical evaluation. Progesterone has been associated in research literature with sleep regulation and neurologic effects, while testosterone in women has been studied in relation to mood, bone density, and muscle mass.

In men, testosterone deficiency may present with symptoms such as fatigue, reduced motivation, changes in mood, decreased muscle mass, and altered metabolic markers. Sharlin Health and Neurology highlighted that laboratory reference ranges reflect statistical averages rather than optimal physiologic targets, and that interpretation should occur within a broader clinical context.

The clinic also addressed the growing number of hormone-focused practices in the Springfield region. It advised patients to consider provider training, medical background, and experience in managing hormone therapy beyond symptom relief, including cardiovascular, metabolic, and neurologic considerations.

Sharlin Health and Neurology reports that bioidentical hormone pellet therapy is one delivery method used in its practice for certain patients. Pellet therapy provides sustained hormone release over several months, which may reduce daily dosing variability. Treatment intervals vary by individual, and all therapies are preceded by clinical assessment and laboratory testing.

The practice further stated that hormone replacement therapy is not appropriate for all individuals. Contraindications may include certain hormone-sensitive cancers, active liver disease, unexplained bleeding, or clotting disorders without physician clearance. Comprehensive evaluation is required before initiating treatment.

Sharlin Health and Neurology provides in-person consultations in Springfield and evaluates patients based on symptoms, laboratory findings, medical history, and individualized risk assessment.

Additional information about hormone evaluation services is available at:
https://sharlinregeneration.com/contact-us/

About Sharlin Health and Neurology

Sharlin Health and Neurology is a Springfield, Missouri-based medical practice specializing in neurologic care and comprehensive health evaluation. The clinic provides patient-centered services with a focus on evidence-based medicine and individualized treatment planning.

Contact Information:

Sharlin Health & Neurology functional Medicine

5528 North Farmer Branch Road
Ozark, MO 65721
United States

Ken Sharlin
(417) 485-4330
https://functionalmedicine.doctor/